Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Girard

Showing results (101-110 of 113) with videos related to

Pageof 12
Sort By:
European Journal of Neurology|May 18, 2022
Confirmed disability progression as a marker of permanent disability in multiple sclerosisSifat Sharmin, Francesca Bovis, Charles Malpas, et al.
PLOS Digital Health|July 25, 2024
Machine-learning-based prediction of disability progression in multiple sclerosis: An observational, international, multi-center studyEdward De Brouwer, Thijs Becker, Lorin Werthen-Brabants, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 21, 2023
Comparative effectiveness in multiple sclerosis: A methodological comparisonIzanne Roos, Ibrahima Diouf, Sifat Sharmin, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 11, 2021
Determinants of therapeutic lag in multiple sclerosisIzanne Roos, Emmanuelle Leray, Federico Frascoli, et al.
Journal of Neurology|April 19, 2026
Predicting disease progression in multiple sclerosis with clinically accessible information and technologyTom A N Fuchs, Menno M Schoonheim, Eva M M Strijbis, et al.
European Journal of Neurology|January 24, 2023
Variability of the response to immunotherapy among subgroups of patients with multiple sclerosisIbrahima Diouf, Charles B Malpas, Sifat Sharmin, et al.
Neurology|August 17, 2022
Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple SclerosisIzanne Roos, Charles Malpas, Emmanuelle Leray, et al.
CNS Drugs|September 18, 2021
Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International CohortsSifat Sharmin, Mathilde Lefort, Johanna Balslev Andersen, et al.
Multiple Sclerosis and Related Disorders|June 11, 2021
The effectiveness of natalizumab vs fingolimod-A comparison of international registry studiesJohanna B Andersen, Sifat Sharmin, Mathilde Lefort, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|May 20, 2026
Comparative effectiveness of ocrelizumab in subgroups of patients with multiple sclerosis: a multi-registry observational cohort studyIzanne Roos, Sifat Sharmin, Dana Horakova, et al.
Pageof 12

Showing results (101-110 of 113) with videos related to

Sort By:
Pageof 12
European Journal of Neurology|May 18, 2022
Confirmed disability progression as a marker of permanent disability in multiple sclerosisSifat Sharmin, Francesca Bovis, Charles Malpas, et al.
PLOS Digital Health|July 25, 2024
Machine-learning-based prediction of disability progression in multiple sclerosis: An observational, international, multi-center studyEdward De Brouwer, Thijs Becker, Lorin Werthen-Brabants, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 21, 2023
Comparative effectiveness in multiple sclerosis: A methodological comparisonIzanne Roos, Ibrahima Diouf, Sifat Sharmin, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 11, 2021
Determinants of therapeutic lag in multiple sclerosisIzanne Roos, Emmanuelle Leray, Federico Frascoli, et al.
Journal of Neurology|April 19, 2026
Predicting disease progression in multiple sclerosis with clinically accessible information and technologyTom A N Fuchs, Menno M Schoonheim, Eva M M Strijbis, et al.
European Journal of Neurology|January 24, 2023
Variability of the response to immunotherapy among subgroups of patients with multiple sclerosisIbrahima Diouf, Charles B Malpas, Sifat Sharmin, et al.
Neurology|August 17, 2022
Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple SclerosisIzanne Roos, Charles Malpas, Emmanuelle Leray, et al.
CNS Drugs|September 18, 2021
Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International CohortsSifat Sharmin, Mathilde Lefort, Johanna Balslev Andersen, et al.
Multiple Sclerosis and Related Disorders|June 11, 2021
The effectiveness of natalizumab vs fingolimod-A comparison of international registry studiesJohanna B Andersen, Sifat Sharmin, Mathilde Lefort, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|May 20, 2026
Comparative effectiveness of ocrelizumab in subgroups of patients with multiple sclerosis: a multi-registry observational cohort studyIzanne Roos, Sifat Sharmin, Dana Horakova, et al.
Pageof 12